Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | M5A-IL2 |
Synonyms | |
Therapy Description |
M5A-IL2 ICK comprises an anti-CEA antibody fused to human IL-2, which potentially induces an immune response against tumor cells expressing CEA, resulting in tumor growth inhibition (PMID: 32117587). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
M5A-IL2 | M5A-ICK|M5A-IL2 immunocytokine|M5A-IL-2 | CEACAM5 Antibody 8 | M5A-IL2 is an immunocytokine comprising an anti-CEA antibody fused to human IL-2, which potentially induces an immune response against tumor cells expressing CEA, resulting in tumor growth inhibition (PMID: 32117587). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06130826 | Phase I | M5A-IL2 | Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer | Recruiting | USA | 0 |